The 9th CAR-TCR Summit Europe returns to London on February 24–26, 2026, once again bringing together leaders in CAR-T, TCR-T, CAR-NK, CAR-Treg, in-vivo cell engineering, and next-generation immune cell platforms. Hosted at the Park Plaza Victoria and organized by Hanson Wade, the summit has become Europe’s most comprehensive industry-focused forum bridging scientific innovation, translational progress, manufacturing, regulation, and commercialization.
Present Landscape of the Field
This year’s program centers on advancing next-generation immune cell engineering. Key themes include novel receptor design, multi-target constructs, new cell types such as NK and macrophages, and emerging strategies to strengthen persistence and overcome resistance in both hematologic and solid tumors. The summit also highlights the growing role of in-vivo CAR and TCR technologies, which are rapidly gaining interest for their potential to reduce manufacturing complexity and broaden access.
Key Scientific and Strategic Themes for 2026
As in previous years, the summit maintains a full end-to-end approach, spanning discovery through commercialization. Core focus areas for 2026 include:
- novel CAR, TCR, NK, and Macrophage designs
- engineering to improve durability and solutions to overcome bottlenecks in manufacturing
- regulatory approval
- commercialization
These discussions come at a time when more programs than ever are entering early and mid-stage clinical development, amplifying the need for harmonized regulatory expectations, efficient manufacturing solutions, and commercially viable pathways.
What’s New for 2026
The upcoming summit introduces several highly anticipated sessions focused on real-world performance, next-generation platforms, and emerging indications.
Featured presentations include:
- Real-world outcomes for approved CAR-T therapies and new clinical data for upcoming constructs
Valentin Ortiz, Hospital Clínic Barcelona - Lymphodepletion-free CAR-T therapies for autoimmune diseas
- Maria Eugenia Alonso Ferrero, Alexion Pharmaceuticals
- ENaBL platform data — a nanobody-targeted lentiviral system enabling in-vivo cell reprogramming, Philippe Parone, EsoBiotec
These sessions reflect the sector’s continued evolution toward safer, more durable, and more accessible therapies.
New Bootcamps
Two specialized bootcamps will help teams refine their development and investment strategies:
- Regulatory Bootcamp- Participants will examine evolving regulatory frameworks across Europe, the U.S., and Asia, learn how modernization initiatives affect review timelines, and gain practical guidance on planning for European market entry.
- Investment & Partnerships Bootcamp-Designed to support early-stage innovation, this session covers initiating investigator-led trials in China to generate early human data, navigating European non-dilutive funding through cluster models and consortia, and aligning value expectations with pharma and investors.
These bootcamps offer hands-on guidance at a time when companies must balance scientific progress with clear, commercially grounded development plans.
A Strategic Meeting Point for Science, Manufacturing & Partnerships
Johnson & Johnson, Hospital Clínic Barcelona, and Immatics—providing attendees with a forum to exchange knowledge and engage with stakeholders involved in cell therapy development across Europe and internationally.
As next-generation immune cell platforms progress toward clinical application and in-vivo technologies continue to advance, the 2026 CAR-TCR Summit Europe offers a structured setting to review scientific developments, manufacturing approaches, and evolving commercial and regulatory pathways shaping the direction of engineered cell therapies.
Event Details
Dates: February 24–26, 2026
Location: Park Plaza Victoria London
Address: 239 Vauxhall Bridge Road, London SW1V 1EQ, United Kingdom
Organizer: Hanson Wade Limited
Phone: +44 (0)20 3141 8700
Email: [email protected]
Venue Phone: +44 333 400 6142